These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10858489)

  • 1. Defining patient risks from expanded preventive therapies.
    Tolman KG
    Am J Cardiol; 2000 Jun; 85(12A):15E-9E. PubMed ID: 10858489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study.
    Avins AL; Manos MM; Ackerson L; Zhao W; Murphy R; Levin TR; Watson DJ; Hwang PM; Replogle A; Levine JG
    Drug Saf; 2008; 31(4):325-34. PubMed ID: 18366243
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patients with elevated baseline liver enzymes do not have higher frequency of hepatotoxicity from lovastatin than those with normal baseline liver enzymes.
    Vuppalanchi R; Teal E; Chalasani N
    Am J Med Sci; 2005 Feb; 329(2):62-5. PubMed ID: 15711421
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The liver and lovastatin.
    Tolman KG
    Am J Cardiol; 2002 Jun; 89(12):1374-80. PubMed ID: 12062731
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Statin-related aminotransferase elevation according to baseline aminotransferases level in real practice in Korea.
    Kim HS; Lee SH; Kim H; Lee SH; Cho JH; Lee H; Yim HW; Kim SH; Choi IY; Yoon KH; Kim JH
    J Clin Pharm Ther; 2016 Jun; 41(3):266-72. PubMed ID: 27015878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of transient elevations in alanine aminotransferase during long-term treatment with acetaminophen in osteoarthritis clinical trials.
    Kuffner EK; Temple AR; Cooper KM; Baggish JS; Parenti DL
    Curr Med Res Opin; 2006 Nov; 22(11):2137-48. PubMed ID: 17076974
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of statins: effects on muscle and the liver.
    Vasudevan AR; Hamirani YS; Jones PH
    Cleve Clin J Med; 2005 Nov; 72(11):990-3, 996-1001. PubMed ID: 16315438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced liver injury.
    Leise MD; Poterucha JJ; Talwalkar JA
    Mayo Clin Proc; 2014 Jan; 89(1):95-106. PubMed ID: 24388027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy.
    Tzefos M; Olin JL
    J Clin Lipidol; 2011; 5(6):450-9. PubMed ID: 22108148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all.
    Grieco A; Miele L; Pompili M; Biolato M; Vecchio FM; Grattagliano I; Gasbarrini G
    J Hepatol; 2009 Jun; 50(6):1273-7. PubMed ID: 19398239
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Impact of lipid lowering therapy on liver function].
    Paragh G; Fülöp P
    Orv Hetil; 2009 Jun; 150(26):1205-12. PubMed ID: 19546077
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group.
    Lambert M; Lupien PJ; Gagné C; Lévy E; Blaichman S; Langlois S; Hayden M; Rose V; Clarke JT; Wolfe BM; Clarson C; Parsons H; Stephure DK; Potvin D; Lambert J
    Pediatrics; 1996 May; 97(5):619-28. PubMed ID: 8628597
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of statins on the liver: clinical analysis of patients with ischemic stroke.
    Zhang LS; Liu ZX; Lü W; Hu XY
    Chin Med J (Engl); 2011 Mar; 124(6):897-900. PubMed ID: 21518599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering agents that cause drug-induced hepatotoxicity.
    Bhardwaj SS; Chalasani N
    Clin Liver Dis; 2007 Aug; 11(3):597-613, vii. PubMed ID: 17723922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative tolerability of the HMG-CoA reductase inhibitors.
    Farmer JA; Torre-Amione G
    Drug Saf; 2000 Sep; 23(3):197-213. PubMed ID: 11005703
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Change in ALT levels after administration of HMG-CoA reductase inhibitors to subjects with pretreatment levels three times the upper normal limit in clinical practice.
    Kim H; Lee H; Kim TM; Yang SJ; Baik SY; Lee SH; Cho JH; Lee H; Yim HW; Choi IY; Yoon KH; Kim HS
    Cardiovasc Ther; 2018 Jun; 36(3):e12324. PubMed ID: 29464863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid-lowering agents and hepatotoxicity.
    Demyen M; Alkhalloufi K; Pyrsopoulos NT
    Clin Liver Dis; 2013 Nov; 17(4):699-714, x. PubMed ID: 24099026
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatotoxicity of hydroxy-methyl-glutaryl-coenzyme A reductase inhibitors.
    Ballarè M; Campanini M; Airoldi G; Zaccala G; Bertoncelli MC; Cornaglia G; Porzio M; Monteverde A
    Minerva Gastroenterol Dietol; 1992; 38(1):41-4. PubMed ID: 1520752
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Mechanisms of hepatotoxicity].
    Bertolami MC
    Arq Bras Cardiol; 2005 Oct; 85 Suppl 5():25-7. PubMed ID: 16400394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study.
    Blais L; Desgagné A; LeLorier J
    Arch Intern Med; 2000 Aug 14-28; 160(15):2363-8. PubMed ID: 10927735
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.